378 related articles for article (PubMed ID: 16631290)
1. Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer.
Susce MT; Murray-Carmichael E; de Leon J
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1356-8. PubMed ID: 16631290
[TBL] [Abstract][Full Text] [Related]
2. Complicated pain management in a CYP450 2D6 poor metabolizer.
Foster A; Mobley E; Wang Z
Pain Pract; 2007 Dec; 7(4):352-6. PubMed ID: 17986163
[TBL] [Abstract][Full Text] [Related]
3. CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study.
VanderVaart S; Berger H; Sistonen J; Madadi P; Matok I; Gijsen VM; de Wildt SN; Taddio A; Ross CJ; Carleton BC; Hayden MR; Koren G
Ther Drug Monit; 2011 Aug; 33(4):425-32. PubMed ID: 21743374
[TBL] [Abstract][Full Text] [Related]
4. Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors.
Thompson CM; Wojno H; Greiner E; May EL; Rice KC; Selley DE
J Pharmacol Exp Ther; 2004 Feb; 308(2):547-54. PubMed ID: 14600248
[TBL] [Abstract][Full Text] [Related]
5. Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia.
Zwisler ST; Enggaard TP; Mikkelsen S; Brosen K; Sindrup SH
Acta Anaesthesiol Scand; 2010 Feb; 54(2):232-40. PubMed ID: 19719813
[TBL] [Abstract][Full Text] [Related]
6. Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype.
Mikus G; Trausch B; Rodewald C; Hofmann U; Richter K; Gramatté T; Eichelbaum M
Clin Pharmacol Ther; 1997 Apr; 61(4):459-66. PubMed ID: 9129563
[TBL] [Abstract][Full Text] [Related]
7. Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid-Treated Oncology Patients.
Reizine N; Danahey K; Schierer E; Liu P; Middlestadt M; Ludwig J; Truong TM; van Wijk XMR; Yeo KJ; Malec M; Ratain MJ; O'Donnell PH
Oncologist; 2021 Nov; 26(11):e2042-e2052. PubMed ID: 34423496
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions.
Caraco Y; Sheller J; Wood AJ
J Pharmacol Exp Ther; 1996 Sep; 278(3):1165-74. PubMed ID: 8819499
[TBL] [Abstract][Full Text] [Related]
9. The influence of pharmacogenetics on opioid analgesia: studies with codeine and oxycodone in the Sprague-Dawley/Dark Agouti rat model.
Cleary J; Mikus G; Somogyi A; Bochner F
J Pharmacol Exp Ther; 1994 Dec; 271(3):1528-34. PubMed ID: 7996467
[TBL] [Abstract][Full Text] [Related]
10. The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism.
Zwisler ST; Enggaard TP; Noehr-Jensen L; Pedersen RS; Mikkelsen S; Nielsen F; Brosen K; Sindrup SH
Basic Clin Pharmacol Toxicol; 2009 Apr; 104(4):335-44. PubMed ID: 19281600
[TBL] [Abstract][Full Text] [Related]
11. Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers.
de Leon J; Dinsmore L; Wedlund P
J Clin Psychopharmacol; 2003 Aug; 23(4):420-1. PubMed ID: 12920424
[No Abstract] [Full Text] [Related]
12. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication.
Kirchheiner J; Schmidt H; Tzvetkov M; Keulen JT; Lötsch J; Roots I; Brockmöller J
Pharmacogenomics J; 2007 Aug; 7(4):257-65. PubMed ID: 16819548
[TBL] [Abstract][Full Text] [Related]
13. CYP2D6 polymorphism in relation to tramadol metabolism: a study of faroese patients.
Halling J; Weihe P; Brosen K
Ther Drug Monit; 2008 Jun; 30(3):271-5. PubMed ID: 18520597
[TBL] [Abstract][Full Text] [Related]
14. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone).
Matic M; Nijenhuis M; Soree B; de Boer-Veger NJ; Buunk AM; Houwink EJF; Mulder H; Rongen GAPJM; Weide JV; Wilffert B; Swen JJ; Guchelaar HJ; Deneer VHM; van Schaik RHN
Eur J Hum Genet; 2022 Oct; 30(10):1105-1113. PubMed ID: 34267337
[TBL] [Abstract][Full Text] [Related]
15. Implementing a pragmatic clinical trial to tailor opioids for acute pain on behalf of the IGNITE ADOPT PGx investigators.
Cavallari LH; Cicali E; Wiisanen K; Fillingim RB; Chakraborty H; Myers RA; Blake KV; Asiyanbola B; Baye JF; Bronson WH; Cook KJ; Elwood EN; Gray CF; Gong Y; Hines L; Kannry J; Kucher N; Lynch S; Nguyen KA; Obeng AO; Pratt VM; Prieto HA; Ramos M; Sadeghpour A; Singh R; Rosenman M; Starostik P; Thomas CD; Tillman E; Dexter PR; Horowitz CR; Orlando LA; Peterson JF; Skaar TC; Van Driest SL; Volpi S; Voora D; Parvataneni HK; Johnson JA;
Clin Transl Sci; 2022 Oct; 15(10):2479-2492. PubMed ID: 35899435
[TBL] [Abstract][Full Text] [Related]
16. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes.
Stamer UM; Musshoff F; Kobilay M; Madea B; Hoeft A; Stuber F
Clin Pharmacol Ther; 2007 Jul; 82(1):41-7. PubMed ID: 17361124
[TBL] [Abstract][Full Text] [Related]
17. CYP2D6-inhibiting drugs and the increased risk of fall-related injuries due to newly initiated opioid treatment--a Swedish, register-based case-crossover study.
Möller J; Laflamme L; Söderberg Löfdal K
Basic Clin Pharmacol Toxicol; 2015 Feb; 116(2):134-9. PubMed ID: 24975450
[TBL] [Abstract][Full Text] [Related]
18. Influence of Cytochrome P450, Family 2, Subfamily D, Polypeptide 6 (CYP2D6) polymorphisms on pain sensitivity and clinical response to weak opioid analgesics.
Zahari Z; Ismail R
Drug Metab Pharmacokinet; 2014; 29(1):29-43. PubMed ID: 23759977
[TBL] [Abstract][Full Text] [Related]
19. Observations on the urine metabolic profile of codeine in pain patients.
Yee DA; Atayee RS; Best BM; Ma JD
J Anal Toxicol; 2014 Mar; 38(2):86-91. PubMed ID: 24396053
[TBL] [Abstract][Full Text] [Related]
20. CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants.
Haufroid V; Hantson P
Clin Toxicol (Phila); 2015 Jul; 53(6):501-10. PubMed ID: 25998998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
